2-[3-[3-(difluoromethoxy)-5-methoxy-4-prop-1-en-2-ylphenyl]pyrazolo[1,5-a]pyridin-6-yl]-2-methylpropanenitrile
C22H21F2N3O2 — CID 155727545
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[3-[3-(difluoromethoxy)-5-methoxy-4-prop-1-en-2-ylphenyl]pyrazolo[1,5-a]pyridin-6-yl]-2-methylpropanenitrile
2-[3-[3-(difluoromethoxy)-5-methoxy-4-prop-1-en-2-ylphenyl]pyrazolo[1,5-a]pyridin-6-yl]-2-methylpropanenitrile (PubChem CID 155727545) has the molecular formula C22H21F2N3O2 and a molecular weight of 397.43 g/mol. Its IUPAC name is 2-[3-[3-(difluoromethoxy)-5-methoxy-4-prop-1-en-2-ylphenyl]pyrazolo[1,5-a]pyridin-6-yl]-2-methylpropanenitrile.
Molecular Properties
| Compound Name | 2-[3-[3-(difluoromethoxy)-5-methoxy-4-prop-1-en-2-ylphenyl]pyrazolo[1,5-a]pyridin-6-yl]-2-methylpropanenitrile |
|---|---|
| PubChem CID | 155727545 |
| Molecular Formula | C22H21F2N3O2 |
| Molecular Weight | 397.43 g/mol |
| Exact Mass | 397.16 |
| IUPAC Name | 2-[3-[3-(difluoromethoxy)-5-methoxy-4-prop-1-en-2-ylphenyl]pyrazolo[1,5-a]pyridin-6-yl]-2-methylpropanenitrile |
| SMILES | C=C(C)c1c(OC)cc(-c2cnn3cc(C(C)(C)C#N)ccc23)cc1OC(F)F |
| InChI | InChI=1S/C22H21F2N3O2/c1-13(2)20-18(28-5)8-14(9-19(20)29-21(23)24)16-10-26-27-11-15(6-7-17(16)27)22(3,4)12-25/h6-11,21H,1H2,2-5H3 |
| InChIKey | DCRMDWGTGAVHBY-UHFFFAOYSA-N |
| XLogP | 5.45 |
| TPSA | 59.55 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 397.43 |
| LogP ≤ 5 | 5.45 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155727545 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.